Pre-clinical studies have shown that cell lines with ARID1A mutations are sensitive to EZH2 inhibitors [59], such as tazemetostat, which are currently approved for the treatment of FL and are in clinical trial development for DLBCL. The gene discussed is ARID1A; the disease is diffuse large B-cell lymphoma.